Intervening in the neuropsychiatric features of Parkinson’s disease

References

• Tandberg E, Larsen JP, Aarsland D et al. The occurrence of depression in Parkinson’s disease. A community-based study. Arch. Neurol.53, 175–179 (1996).
   PubMed Web of Science ®Google Scholar
• Kuzis G, Sabe L, Tiberti C, Leiguarda R, Starkstein SE. Cognitive functions in major depression and Parkinson disease. Arch. Neurol.54, 982–986 (1997).
   PubMedGoogle Scholar
• Marsh L, Williams JR, Rocco M et al. Psychiatric comorbidities in patients with Parkinson disease and psychosis. Neurology63, 293–300 (2004).
   PubMed Web of Science ®Google Scholar
• Weintraub D, Morales KH, Duda JE, Moberg PJ, Stern MB. Frequency and correlates of co-morbid psychosis and depression in Parkinson’s disease. Parkinsonism Relat. Disord.12, 427–431 (2006).
   PubMed Web of Science ®Google Scholar
• Rojo A, Aguilar M, Garolera MT et al. Depression in Parkinson’s disease: clinical correlates and outcome. Parkinsonism Relat. Disord.10, 23–28 (2003).
   PubMed Web of Science ®Google Scholar
• Marsh L, McDonald WM, Cummings J, Ravina B; NINDS/NIMH Work Group on Depression and Parkinson’s Disease. Provisional diagnostic criteria for depression in Parkinson’s disease: report of an NINDS/NIMH Work Group. Mov. Disord.21, 148–158 (2006).
   PubMed Web of Science ®Google Scholar
• Ehrt U, Bronnick K, Leentjens AF, Larsen JP, Aarsland D. Depressive symptom profile in Parkinson’s disease: a comparison with depression in elderly patients without Parkinson’s disease. Int. J. Geriatr. Psychiatry21, 252–258 (2006).
   PubMed Web of Science ®Google Scholar
• Shulman LM, Taback RL, Rabinstein AA et al. Non-recognition of depression and other non-motor symptoms in Parkinson’s disease. Parkinsonism Relat. Disord.8, 193–197 (2002).
   PubMed Web of Science ®Google Scholar
• Weintraub D, Moberg PJ, Duda JE et al. Recognition and treatment of depression in Parkinson’s disease. J. Geriatr. Psychiatry Neurol.16, 178–183 (2003).
   PubMed Web of Science ®Google Scholar
• Ehmann TS, Beninger RJ, Gawel MJ et al. Depressive symptoms in Parkinson’s disease: a comparison with disabled control subjects. J. Geriatr. Psychiatry Neurol.2, 3–9 (1989).
   PubMedGoogle Scholar
• Ishihara L, Brayne C. A systematic review of depression and mental illness preceding Parkinson’s disease. Acta Neurol. Scand.113, 211–220 (2006).
   PubMed Web of Science ®Google Scholar
• Remy P, Doder M, Lees A, Turjanski N, Brooks D. Depression in Parkinson’s disease: loss of dopamine and noradrenaline innervation in the limbic system. Brain128, 1314–1322 (2005).
   PubMed Web of Science ®Google Scholar
• Burn DJ, Tiangyou W, Allcock LM, Davison J, Chinnery PF. Allelic variation of a functional polymorphism in the serotonin transporter gene and depression in Parkinson’s disease. Parkinsonism Relat. Disord.12, 139–141 (2006).
   PubMed Web of Science ®Google Scholar
• Leentjens AF, Scholtissen B, Vreeling FW, Verhey FR. The serotonergic hypothesis for depression in Parkinson’s disease: an experimental approach. Neuropsychopharmacology31, 1009–1015 (2006).
   PubMed Web of Science ®Google Scholar
• Richard IH, Kurlan R; Parkinson Study Group. A survey of antidepressant use in Parkinson’s disease. Neurology49, 1168–1170 (1997).
   PubMed Web of Science ®Google Scholar
• Chung TH, Deane KHO, Ghazi-Noori S et al. Systematic review of antidepressant therapies in Parkinson’s disease. Parkinsonism Relat. Disord.10, 59–65 (2003).
   PubMed Web of Science ®Google Scholar
• Leentjens AF, Vreeling FW, Luijckx GJ et al. SSRIs in the treatment of depression in Parkinson’s disease. Int. J. Geriatr. Psychiatry18, 552–554 (2003).
   PubMed Web of Science ®Google Scholar
• Weintraub D, Morales KH, Moberg PJ et al. Antidepressant studies in Parkinson’s disease: a review and meta-analysis. Mov. Disord.20, 1161–1169 (2005).
   PubMed Web of Science ®Google Scholar
• Rektorova I, Rektor I, Bares M et al. Pramipexole and pergolide in the treatment of depression in Parkinson’s disease: a national multicentre prospective randomized study. Eur. J. Neurol.10, 399–406 (2003).
   PubMed Web of Science ®Google Scholar
• Barone P, Scarzella L, Marconi R et al. Pramipexole versus sertraline in the treatment of depression in Parkinson’s disease: a national multicenter parallel-group randomized study. J. Neurol.253, 601–607 (2006).
   PubMed Web of Science ®Google Scholar
• Allain H, Cougnard J, Neukirch H-C et al. Selegiline in de novo parkinsonian patients: the French selegiline multicenter trial (FSMT). Acta Neurol. Scand.84(Suppl. 136), 73–78 (1991).
   PubMedGoogle Scholar
• Bodkin JA, Amsterdam JD. Transdermal selegiline in major depression: a double-blind, placebo-controlled, parallel-group study in outpatients. Am. J. Psychiatry159, 1869–1875 (2002).
   PubMed Web of Science ®Google Scholar
• Moellentine C, Rummans T, Ahlskog JE et al. Effectiveness of ECT in patients with parkinsonism. J. Neuropsychiatry Clin. Neurosci.10, 187–193 (1998).
   PubMed Web of Science ®Google Scholar
• Weintraub D, Oehlberg KA, Katz IR, Stern MB. Test characteristics of the 15-item geriatric depression scale and Hamilton depression rating scale in Parkinson disease. Am. J. Geriatr. Psychiatry14, 169–175 (2006).
   PubMed Web of Science ®Google Scholar
• McDonald WM, Holtzheimer PE, Haber M, Vitek JL, McWhorter K, Delong M. Validity of the 30-item geriatric depression scale in patients with Parkinson’s disease. Mov. Disord.21, 1618–1622 (2006).
   PubMed Web of Science ®Google Scholar
• Alexopoulos GS, Katz IR, Reynolds CF III, Carpenter D, Docherty JP; Expert Consensus Panel for Pharmacotherapy of Depressive Disorders in Older Patients. The expert consensus guideline series. Pharmacotherapy of depressive disorders in older patients. Postgrad. Med.1–86 (2001).
   PubMed Web of Science ®Google Scholar
• Fénelon G, Mahieux F, Huon R et al. Hallucinations in Parkinson’s disease: prevalence, phenomenology, and risk factors. Brain123, 733–745 (2000).
   PubMed Web of Science ®Google Scholar
• Aarsland D, Larsen JP, Cummings JL et al. Prevalence and clinical correlates of psychotic symptoms in Parkinson disease. Arch. Neurol.56, 595–601 (1999).
   PubMed Web of Science ®Google Scholar
• Pacchetti C, Manni R, Zangaglia R et al. Relationship between hallucinations, delusions, and rapid eye movement sleep behavior disorder in Parkinson’s disease. Mov. Disord.20, 1439–1448 (2005).
   PubMed Web of Science ®Google Scholar
• Feldman B, Chapman J, Korczyn AD. Apolipoprotein ε4 advances appearance of psychosis in patients with Parkinson’s disease. Acta Neurol. Scand.113, 14–17 (2006).
   PubMed Web of Science ®Google Scholar
• Marsh L, Williams JR, Rocco M, Grill S, Munro C, Dawson TM. Psychiatric comorbidities in patients with Parkinson disease and psychosis. Neurology63, 293–300 (2004).
   PubMed Web of Science ®Google Scholar
• Aarsland D, Ballard C, Larsen JP, McKeith I. A comparative study of psychiatric symptoms in dementia with Lewy bodies and Parkinson’s disease with and without dementia. Int. J. Geriatr. Psychiatry16, 528–536 (2001).
   PubMed Web of Science ®Google Scholar
• Oishi N, Udaka F, Kameyama M, Sawamoto N, Hashikawa K, Fukuyama H. Regional cerebral blood flow in Parkinson disease with nonpsychotic visual hallucinations. Neurology65, 1708–1715 (2005).
   PubMed Web of Science ®Google Scholar
• Matsui H, Nishinaka K, Oda M et al. Hypoperfusion of the visual pathway in parkinsonian patients with visual hallucinations. Mov. Disord.21, 2140–2144 (2006).
   PubMed Web of Science ®Google Scholar
• Matsui H, Nishinaka K, Oda M et al. Hypoperfusion of the auditory and prefrontal cortices in Parkinsonian patients with verbal hallucinations. Mov. Disord.21, 2165–2169 (2006).
   PubMed Web of Science ®Google Scholar
• Friedman JH, Factor SA. Atypical antipsychotics in the treatment of drug-induced psychosis in Parkinson’s disease. Mov. Disord.15, 201–211 (2000).
   PubMed Web of Science ®Google Scholar
• Ondo WG, Tintner R, Voung KD, Lai D, Ringholz G. Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson’s disease. Mov. Disord.20, 958–963 (2005).
   PubMed Web of Science ®Google Scholar
• Rabey JM, Prokhorov T, Miniovitz A, Dobronevsky E, Klein C. Effect of quetiapine in psychotic Parkinson’s disease patients: a double-blind labeled study of 3 months’ duration. Mov. Disord.22, 313–318 (2007).
   PubMed Web of Science ®Google Scholar
• The Parkinson Study Group. Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson’s disease. N. Engl. J. Med.340, 757–763 (1999).
   PubMed Web of Science ®Google Scholar
• Friedman JH, Barman RM, Goetz CG et al. Open-label flexible-dose pilot study to evaluate the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson’s disease. Mov. Disord.21, 2078–2081 (2006).
   PubMed Web of Science ®Google Scholar
• Fabbrini G, Barbanti P, Aurilia C et al. Donepezil in the treatment of hallucinations and delusions in Parkinson’s disease. Neurol. Sci.23, 41–43 (2002).
   PubMed Web of Science ®Google Scholar
• Reading PJ, Luce AK, McKeith IJ. Rivastigmine in the treatment of parkinsonian psychosis and cognitive impairment: preliminary findings from an open trial. Mov. Disord.16, 1171–1195 (2001).
   PubMed Web of Science ®Google Scholar
• Bullock R, Cameron A. Rivastigmine for the treatment of dementia and visual hallucinations associated with Parkinson’s disease: a case series. Curr. Med. Res. Opin.18, 258–264 (2002).
   PubMed Web of Science ®Google Scholar
• Voon V, Lang AE. Antidepressants in the treatment of psychosis with comorbid depression in Parkinson disease. Clin. Neuropharmacol.27, 90–92 (2004).
   PubMed Web of Science ®Google Scholar
• Meco G, Bernardi S. Antidepressant use in treatment of psychosis with comorbid depression in Parkinson’s disease. Prog. Neuropsychopharmacol. Biol. Psychiatry31, 311–313 (2007).
   PubMed Web of Science ®Google Scholar
• Friedberg G, Zoldan J, Weizman A et al. Parkinson Psychosis Rating Scale: a practical instrument for grading psychosis in Parkinson’s disease. Clin. Neuropharmacol.21, 280–284 (1998).
   PubMed Web of Science ®Google Scholar
• Aarsland D, Zaccai J, Brayne C. A systematic review of prevalence studies of dementia in Parkinson’s disease. Mov. Disord.20, 1255–1263 (2005).
   PubMed Web of Science ®Google Scholar
• Aarsland D, Andersen K, Larsen JP et al. Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch. Neurol.60, 387–392 (2003).
   PubMed Web of Science ®Google Scholar
• Muslimovic D, Post B, Speelman JD, Schmand B. Cognitive profile of patients with newly diagnosed Parkinson disease. Neurology65, 1239–1245 (2005).
   PubMed Web of Science ®Google Scholar
• Aarsland D, Andersen K, Larsen JP et al. The rate of cognitive decline in Parkinson disease. Arch. Neurol.61, 1906–1911 (2004).
   PubMed Web of Science ®Google Scholar
• Pillon B, Deweer B, Agid Y et al. Explicit memory in Alzheimer’s, Huntington’s, and Parkinson’s diseases. Arch. Neurol.50, 374–379 (1993).
   PubMed Web of Science ®Google Scholar
• Turner MA, Moran NF, Kopelman MD. Subcortical dementia. Br. J. Psychiatry180, 148–151 (2002).
   PubMed Web of Science ®Google Scholar
• Weintraub D, Moberg PJ, Culbertson WC, Duda JE, Stern MB. Evidence for impaired encoding and retrieval memory profiles in Parkinson disease. Cogn. Behav. Neurol.17, 195–200 (2004).
   PubMedGoogle Scholar
• Hurtig HI, Trojanowski JQ, Galvin J et al. α-synuclein cortical Lewy bodies correlate with dementia in Parkinson’s disease. Neurology54, 1916–1921 (2000).
   PubMed Web of Science ®Google Scholar
• Kovari E, Gold G, Herrmann FR et al. Lewy body densities in the entorhinal and anterior cingulate cortex predict cognitive deficits in Parkinson’s disease. Acta Neuropathol. (Berl.)106, 83–88 (2003).
   PubMed Web of Science ®Google Scholar
• Braak H, Rub U, Jansen Steur EN, Del Tredici K, de Vos RA. Cognitive status correlates with neuropathologic stage in Parkinson disease. Neurology64, 1404–1410 (2005).
   PubMed Web of Science ®Google Scholar
• Burn DJ, O’Brien JT. Use of functional imaging in parkinsonism and dementia. Mov. Disord.18(Suppl. 6), S88–S95 (2003).
   Google Scholar
• Kaasinen V, Rinne JO. Functional imaging studies of dopamine system and cognition in normal aging and Parkinson’s disease. Neurosci. Biobehav. Rev.26, 785–793 (2002).
   PubMed Web of Science ®Google Scholar
• Hilker R, Thomas AV, Klein JC et al. Dementia in Parkinson disease: functional imaging of cholinergic and dopaminergic pathways. Neurology65, 1716–1722 (2005).
   PubMed Web of Science ®Google Scholar
• Emre M, Aarsland D, Albanese A et al. Rivastigmine for dementia associated with Parkinson’s disease. N. Engl. J. Med.351, 2509–2518 (2004).
   PubMed Web of Science ®Google Scholar
• Poewe W, Wolters E, Emre M et al. Long-term benefits of rivastigmine in dementia associated with Parkinson’s disease: an active treatment extension study. Mov. Disord.21(4), 456–461 (2006).
   PubMed Web of Science ®Google Scholar
• Leroi I, Brandt J, Reich SG et al. Randomized placebo-controlled trial of donepezil in cognitive impairment in Parkinson’s disease. Int. J. Geriatr. Psychiatry19, 1–8 (2004).
   PubMed Web of Science ®Google Scholar
• Ravina B, Putt M, Siderowf A et al. Donepezil for dementia in Parkinson’s disease: a randomised, double blind, placebo controlled, crossover study. J. Neurol. Neurosurg. Psychiatry76, 934–939 (2005).
   PubMed Web of Science ®Google Scholar
• Aarsland D, Mosimann UP, McKeith IJ. Role of cholinesterase inhibitors in Parkinson’s disease and dementia with Lewy bodies. J. Geriatr. Psychiatry Neurol.17, 164–171 (2004).
   PubMed Web of Science ®Google Scholar
• Minett TSC, Thomas A, Wilkinson LM et al. What happens when donepezil is suddenly withdrawn? An open label trial in dementia with Lewy bodies and Parkinson’s disease with dementia. Int. J. Geriatr. Psychiatry18, 988–993 (2003).
   PubMed Web of Science ®Google Scholar
• Nasreddine ZS, Phillips NA, Bédirian V et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J. Am. Geriatr. Soc.53, 695–699 (2005).
   PubMed Web of Science ®Google Scholar
• Marinus J, Visser M, Verwey NA et al. Assessment of cognition in Parkinson’s disease. Neurology61, 1222–1228 (2003).
   PubMed Web of Science ®Google Scholar
• Walsh K, Bennett G. Parkinson’s disease and anxiety. Postgrad. Med. J.77, 89–93 (2001).
   PubMed Web of Science ®Google Scholar
• Richard IH, Justus AW, Kurlan R. Relationship between mood and motor fluctuations in Parkinson’s disease. J. Neuropsychiatry Clin. Neurosci.13, 35–41 (2001).
   PubMed Web of Science ®Google Scholar
• Shiba M, Bower JH, Maraganore DM et al. Anxiety disorders and depressive disorders preceding Parkinson’s Disease: a case-control study. Mov. Disord.15, 669–677 (2000).
   PubMed Web of Science ®Google Scholar
• Isella V, Melzi P, Grimaldi M et al. Clinical, neuropsychological, and morphometric correlates of apathy in Parkinson’s disease. Mov. Disord.17, 366–371 (2002).
   PubMed Web of Science ®Google Scholar
• Kirsch-Darrow L, Fernandez HH, Marsiske M, Okun MS, Bowers D. Dissociating apathy and depression in Parkinson disease. Neurology67, 33–38 (2006).
   PubMed Web of Science ®Google Scholar
• Robert PH, Berr C, Volteau M et al. Apathy in patients with mild cognitive impairment and the risk of developing dementia of Alzheimer’s disease: a one-year follow-up study. Clin. Neurol. Neurosurg.108, 733–736 (2006).
   PubMed Web of Science ®Google Scholar
• Marin RS, Biedrzycki RC, Firinciogullari S. Reliability and validity of the Apathy Evaluation Scale. Psychiatry Res.38, 143–162 (1991).
   PubMed Web of Science ®Google Scholar
• Starkstein SE, Mayberg HS, Preziosi TJ, Andrezejewski P, Leiguarda R, Robinson RG. Reliability, validity, and clinical correlates of apathy in Parkinson’s disease. J. Neuropsychiatry Clin. Neurosci.4, 134–139 (1992).
   PubMed Web of Science ®Google Scholar
• Cummings JL, Arciniegas DB, Brooks BR et al. Defining and diagnosing involuntary emotional expression disorder. CNS Spectr.11(6 Suppl. 6), 1–7 (2006).
   PubMed Web of Science ®Google Scholar
• Driver-Dunckley E, Samanta J, Stacy M. Pathological gambling associated with dopamine agonist therapy in Parkinson’s disease. Neurology61, 422–423 (2003).
   PubMed Web of Science ®Google Scholar
• Nirenberg MJ, Waters C. Compulsive eating and weight gain related to dopamine agonist use. Mov. Disord.21, 524–529 (2006).
   PubMed Web of Science ®Google Scholar
• Klos KJ, Bower JH, Josephs KA, Matsumoto JY, Ahlskog JE. Pathological hypersexuality predominantly linked to adjuvant dopamine agonist therapy in Parkinson’s disease and multiple system atrophy. Parkinsonism Relat. Disord.11, 381–386 (2005).
   PubMed Web of Science ®Google Scholar
• Evans AH, Katzenschlager R, Paviour D et al. Punding in Parkinson’s disease: its relation to the dopamine dysregulation syndrome. Mov. Disord.19, 397–405 (2004).
   PubMed Web of Science ®Google Scholar
• Weintraub D, Siderowf AD, Potenza MN et al. Association of dopamine agonist use with impulse control disorders in Parkinson disease. Arch. Neurol.63, 969–973 (2006).
   PubMed Web of Science ®Google Scholar
• Voon V, Hassan K, Zurowski M et al. Prospective prevalence of pathologic gambling and medication association in Parkinson disease. Neurology66, 1750–1752 (2006).
   PubMed Web of Science ®Google Scholar
• Potenza MN, Leung H-C, Blumberg HP et al. An fMRI Stroop task study in ventromedial prefrontal cortical function in pathological gamblers. Am. J. Psychiatry160, 1990–1994 (2003).
   PubMed Web of Science ®Google Scholar
• Ardouin C, Voon V, Worbe Y et al. Pathological gambling in Parkinson’s disease improves on chronic subthalamic nucleus stimulation. Mov. Disord.21, 1941–1946 (2006).
   PubMed Web of Science ®Google Scholar
• Friedman JH, Chou KL. Sleep and fatigue in Parkinson’s disease. Parkinsonism Relat. Disord.10, S27–S35 (2004).
   PubMed Web of Science ®Google Scholar
• Comella CL, Nardine TM, Diederich NJ, Stebbins GT. Sleep-related violence, injury, and REM sleep behavior disorder in Parkinson’s disease. Neurology51, 526–529 (1998).
   PubMed Web of Science ®Google Scholar
• Schenck CH, Bundlie SR, Mahowald MW. Delayed emergence of a parkinsonian disorder in 38% of 29 older men initially diagnosed with idiopathic rapid eye movement sleep behaviour disorder. Neurology46, 388–393 (1996).
   PubMed Web of Science ®Google Scholar
• Eisensehr I, Linke R, Noachtar S et al. Reduced striatal dopamine transporters in idiopathic rapid eye movement sleep behavior disorder. Comparison with Parkinson’s disease and controls. Brain123, 1155–1160 (2000).
   PubMed Web of Science ®Google Scholar
• Phillips B. Movement disorders: a sleep specialist’s perspective. Neurology62(Suppl. 2), S9–S16 (2004).
   Google Scholar
• Chaudhuri A, Behan PO. Fatigue and basal ganglia. J. Neurol. Sci.179, 34–42 (2000).
   PubMed Web of Science ®Google Scholar
• Hobson DE, Lang AE, Martin WR, Razmy A, Rivest J, Fleming J. Excessive daytime sleepiness and sudden-onset sleep in Parkinson disease: a survey by the Canadian Movement Disorders Group. JAMA287, 455–463 (2002).
   PubMed Web of Science ®Google Scholar
• Gjerstad MD, Alves G, Wentzel-Larsen T, Aarsland D, Larsen JP. Excessive daytime sleepiness in Parkinson disease: is it the drugs or the disease? Neurology67, 853–858 (2006).
   PubMed Web of Science ®Google Scholar
• Abbott RD, Ross GW, White LR et al. Excessive daytime sleepiness and subsequent development of Parkinson disease. Neurology65, 1442–1446 (2005).
   PubMed Web of Science ®Google Scholar
• Ondo WG, Fayle R, Atassi F, Jankovic J. Modafinil for daytime somnolence in Parkinson’s disease: double blind, placebo controlled parallel trial. J. Neurol. Neurosurg. Psychiatry76, 1636–1639 (2005).
   PubMed Web of Science ®Google Scholar
• Menza MA, Golbe LI, Cody RA, Forman NE. Dopamine-related personality traits in Parkinson’s disease. Neurology43, 505–508 (1993).
   PubMed Web of Science ®Google Scholar
• Ishihara L, Brayne C. What is the evidence for a premorbid parkinsonian personality: a systematic review. Mov. Disord.21, 1066–1072 (2006).
   PubMed Web of Science ®Google Scholar
• Kaasinen V, Nurmi E, Bergman J et al. Personality traits and brain dopaminergic function in Parkinson’s disease. Proc. Natl Acad. Sci. USA98, 13272–13277 (2001).
   PubMed Web of Science ®Google Scholar
• Dostrovsky JO, Lozano AM. Mechanisms of deep brain stimulation. Mov. Disord.17, S63–S68 (2002).
   PubMed Web of Science ®Google Scholar
• Krack P, Batir A, Van Blercom N, et al. Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson’s disease. N. Engl. J. Med.13, 1925–1934 (2003).
   Google Scholar
• Schüpbach WMM, Chastan N, Welter ML et al. Stimulation of the subthalamic nucleus in Parkinson’s disease: a 5 year follow up. J. Neurol. Neurosurg. Psychiatry76, 1640–1644 (2005).
   PubMed Web of Science ®Google Scholar
• Voon V, Kubu C, Krack P, Houeto JL, Troster AI. Deep brain stimulation: neuropsychological and neuropsychiatric issues. Mov. Disord.21(Suppl. 14), S305–S327 (2006).
   PubMed Web of Science ®Google Scholar
• Herzog J, Volkmann J, Krack P et al. Two-year follow-up of subthalamic deep brain stimulation in Parkinson’s disease. Mov. Disord.18, 1332–1337 (2003).
   PubMed Web of Science ®Google Scholar
• Smeding HM, Speelman JD, Koning-Haanstra M et al. Neuropsychological effects of bilateral STN stimulation in Parkinson disease: a controlled study. Neurology66, 1830–1836 (2006).
   PubMed Web of Science ®Google Scholar
• Houeto JL, Mesnage V, Mallet L et al. Behavioral disorders, Parkinson’s disease and subthalamic stimulation. J. Neurol. Neurosurg. Psychiatry72, 701–707 (2002).
   PubMed Web of Science ®Google Scholar
• Parsons TD, Rogers SA, Braaten AJ, Woods SP, Troster AI. Cognitive sequelae of subthalamic nucleus deep brain stimulation in Parkinson’s disease: a meta-analysis. Lancet Neurol.5, 578–588 (2006).
   PubMed Web of Science ®Google Scholar
• Berney A, Vingerhoets F, Perrin A et al. Effect on mood of subthalamic DBS for Parkinson’s disease: a consecutive series of 24 patients. Neurology59, 1427–1429 (2002).
   PubMed Web of Science ®Google Scholar
• Miyasaki JM, Shannon K, Voon V et al. Practice Parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology66, 996–1002 (2006).
   PubMed Web of Science ®Google Scholar